|
| |
John Allinson, is a Fellow of the Institute of Biomedical Sciences (FIBMS) and, having spent 22 years in diagnostic laboratories in the National Health Service, has experience in all major fields of clinical pathology. He has managed and developed specialist laboratory services for drug monitoring, trace metals, and immunoassays. During a tenure in a large CRO, he developed analytical services for a large central clinical laboratory conducting all phases of pre-clinical and clinical trials. This work necessitated the validation of more than 100 immunoassays on a variety of analytical platforms.
In 2001-2005 John led the development of new analytical services including the biomarkers laboratory as Laboratory Director of BASI UK.
John is a respected speaker at a number of conferences internationally, addressing the topic of biomarkers, regulatory issues, and the synergies with traditional bioanalytical laboratories. He is a member of the Biomarker Committee of the AAPS Ligand Binding Assay Bioanalytical Focus Group (LBABFG) whose aims are to produce recommendations for the industry for biomarker assays and their validation – the first white paper being published in the AAPS journal -Pharmaceutical Research- in February 2006. |
